Representative measurements of mice treated with INS018_055 (3, 10 or 30 mg per kg, BID) and nintedanib (60 mg per kg, QD) from a showing Masson’s trichrome staining, modified Ashcroft scores and immunohistochemistry (IHC) of collagen 1 and -SMA. n = 10 per group (mean ± s.d.) (Masson’s trichrome staining: group 1 (vehicle) compared to groups 2, 3, 4 and 5, with P = 0.0233, 0.0004, 0.0004 and <0.0001, respectively; group 5 compared to groups 2, 3 and 4, with P = 0.0799, 0.8126 and 0.8289, respectively. Modified Ashcroft: group 1 compared to groups 2, 3, 4 and 5 with P = 0.1021, 0.0071, 0.004 and 0.0001, respectively; group 5 compared to groups 2, 3 and 4 with P = 0.1718, 0.791 and 0.8933, respectively. -SMA: group 1 compared to groups 2–5 with P <= 0.0001; group 5 compared to groups 2, 3 and 4 with P = 0.9689, 0.6125 and >0.9999, respectively. Collagen I: group 1 compared to groups 2–5 with P <= 0.0001; group 5 compared to groups 2, 3 and 4, with P = 0.9985, 0.9986 and >0.9999, respectively). Ordinary one-way ANOVA and post hoc Šídák’s multiple-comparison test were used to assess statistical significance.
